Rise in adverse events for TMJ implants prompts FDA update
The U.S. Food and Drug Administration (FDA) on June 17 released updated information about temporomandibular disorder (TMD) and temporomandibular joint (TMJ) implants, including the number of reported adverse events and ways the agency is engaging with patients. An influx of reports on adverse events related to TMJ implants triggered the FDA to increase engagement with patients diagnosed with TMD and to review postmarket studies. The FDA requires premarket approval (PMA)

